Complement C5a receptor antagonist in the treatment of experimental periodontitis in mice
European Journal of Oral Sciences · 2026
DOI: 10.1111/eos.70054 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Oral Sciences, 2026. Verfasst von Yan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Periodontitis, Receptor, Anaphylatoxin C5a. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Heilongjiang Postdoctoral Financial Assistance, China, National Natural Science Foundation of China, Heilongjiang Province Natural Science Foundation.
Abstract (Originalsprache)
Periodontitis arises from dysbiosis of the oral microbiome and excessive host immune responses, with the C5a–C5aR axis playing a key role in destructive inflammation. This study evaluated the efficacy of the C5aR antagonist W54011 in treating experimental periodontitis in mice. A ligature‐induced periodontitis model combined with localized Porphyromonas gingivalis lipopolysaccharide (LPS) injection was established to mimic human disease progression. Periodontal inflammation was assessed by measuring TNF‐α and IL‐6 levels via enzyme‐linked immunosorbent assay and real‐time quantitative polymerase chain reaction, while C5aR expression was analyzed by western blot and immunohistochemistry. Micro‐computed tomography (micro‐CT) quantified alveolar bone resorption. Results showed that TNF‐α, IL‐6, and C5aR expression was significantly upregulated in periodontitis‐affected mice compared to healthy controls. W54011 treatment effectively suppressed these inflammatory mediators and reduced C5aR expression. Furthermore, micro‐CT revealed that W54011 significantly attenuated bone loss, preserving periodontal architecture. These findings demonstrate that pharmacological blockade of C5aR with W54011 attenuates periodontal inflammation and reduces alveolar bone destruction, suggesting its potential as a novel host‐modulation therapy for periodontitis. The study provides mechanistic insights into C5a–C5aR signaling in periodontitis pathogenesis while proposing a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stomatology, The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin, Heilongjiang, China.
- Department of Prosthodontics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
- Department of Pharmacy, The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- Department of Craniomaxillofacial Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yan Chen, Zhuangying Chen, Yan Li, Junlong Hu, Yue Zhang, Zhongqiang Han, Mingyue Liu
Förderung
- Heilongjiang Postdoctoral Financial Assistance, China
- National Natural Science Foundation of China
- Heilongjiang Province Natural Science Foundation
- Heilongjiang Provincial Health Commission Research Project
Zitieren
APA
Chen, Y., Chen, Z., Li, Y., Hu, J., Zhang, Y., Han, Z., & Liu, M. (2026). Complement C5a receptor antagonist in the treatment of experimental periodontitis in mice. European Journal of Oral Sciences. https://doi.org/10.1111/eos.70054
Vancouver
Chen Y, Chen Z, Li Y, Hu J, Zhang Y, Han Z, et al. Complement C5a receptor antagonist in the treatment of experimental periodontitis in mice. European Journal of Oral Sciences. 2026. doi:10.1111/eos.70054
BibTeX
@article{Chen2026,
author = {Chen, Yan and Chen, Zhuangying and Li, Yan and Hu, Junlong and Zhang, Yue and Han, Zhongqiang and Liu, Mingyue},
title = {Complement C5a receptor antagonist in the treatment of experimental periodontitis in mice},
journal = {European Journal of Oral Sciences},
year = {2026},
doi = {10.1111/eos.70054}
}
EUVIMED